MicroRNA therapeutics for cardiovascular disease: opportunities and obstacles.
In recent years, prominent roles for microRNAs (miRNAs) have been uncovered in several cardiovascular disorders. The ability to therapeutically manipulate miRNA expression and function through systemic or local delivery of miRNA inhibitors, referred to as antimiRs, has triggered enthusiasm for miRNAs as novel therapeutic targets. Here, we focus on the pharmacokinetic and pharmacodynamic properties of current antimiR designs and their relevance to cardiovascular indications, and evaluate the opportunities and obstacles associated with this new therapeutic modality.
miRagen Therapeutics, 6200 Lookout Rd, Boulder, Colorado                 80301, USA.
Eva
E
van Rooij
Eric N
EN
Olson
D000818:Animals; D002317:Cardiovascular Agents / Q000493:pharmacokinetics / Q000494:pharmacology*; D002318:Cardiovascular Diseases / Q000235:genetics / Q000503:physiopathology / Q000628:therapy*; D015195:Drug Design; D005786:Gene Expression Regulation; D006801:Humans; D035683:MicroRNAs / Q000037:antagonists & inhibitors* / Q000378:metabolism
D002317:Cardiovascular Agents; D035683:MicroRNAs